Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is one of the strongest research-driven biotechnology firms globally, known for its antibody discovery capabilities, internal science culture, and successful commercial products across ophthalmology, immunology, oncology, and rare diseases.
- Highest 2026 tier: Tier I
- Biotechnology Firms
- 3 ranking categories
Overview
Regeneron Pharmaceuticals is one of the strongest research-driven biotechnology firms globally, known for its antibody discovery capabilities, internal science culture, and successful commercial products across ophthalmology, immunology, oncology, and rare diseases.
Regeneron’s strength lies in its integrated discovery and development platform. The company has built substantial expertise in antibody engineering, genetic medicine research, and biologics development, while maintaining a culture closely associated with internal scientific productivity. Its 2025 annual report highlighted $14.3 billion in 2025 revenues and four currently marketed blockbuster medicines: Dupixent, EYLEA HD, EYLEA, and Libtayo.
Regeneron Pharmaceuticals is included in 3 2026 ranking categories. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Regeneron Pharmaceuticals |
| Founded | 1988 |
| Institution type | Biotechnology Firms institution |
| Headquarters | Tarrytown, United States |
| Primary focus | Biotechnology Firms |
| Highest 2026 ranking tier | Tier I |
Principal activities
Regeneron’s strength lies in its integrated discovery and development platform. The company has built substantial expertise in antibody engineering, genetic medicine research, and biologics development, while maintaining a culture closely associated with internal scientific productivity. Its 2025 annual report highlighted $14.3 billion in 2025 revenues and four currently marketed blockbuster medicines: Dupixent, EYLEA HD, EYLEA, and Libtayo.
Core capability
Biotechnology Firms
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Biotechnology Firms
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Regeneron’s combination of scientific depth, biologics platform strength, commercial execution, and focused innovation culture supports its Tier I position among global biotechnology firms.
Regeneron Pharmaceuticals is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Regeneron Pharmaceuticals should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Regeneron Pharmaceuticals. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Regeneron Pharmaceuticals |
| Headquarters | Tarrytown, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Biotechnology Firms 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Specialty Pharma Companies 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Vaccine & Immunotherapy Developers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
